242 related articles for article (PubMed ID: 34296214)
21. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
Gu S; Cui D; Chen X; Xiong X; Zhao Y
Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, and evaluation of BCL-2 targeting PROTACs.
Bricelj A; Ng YLD; Gobec M; Kuchta R; Hu W; Javornik Š; Rožič M; Gütschow M; Zheng G; Krönke J; Steinebach C; Sosič I
Chemistry; 2024 May; ():e202400430. PubMed ID: 38818652
[TBL] [Abstract][Full Text] [Related]
23. Sulfatase-Induced In Situ Formulation of Antineoplastic Supra-PROTACs.
Chen N; Zhang Z; Liu X; Wang H; Guo RC; Wang H; Hu B; Shi Y; Zhang P; Liu Z; Yu Z
J Am Chem Soc; 2024 Apr; 146(15):10753-10766. PubMed ID: 38578841
[TBL] [Abstract][Full Text] [Related]
24. Proteolysis-targeting chimera against BCL-X
Kolb R; De U; Khan S; Luo Y; Kim MC; Yu H; Wu C; Mo J; Zhang X; Zhang P; Zhang X; Borcherding N; Koppel D; Fu YX; Zheng SG; Avram D; Zheng G; Zhou D; Zhang W
Nat Commun; 2021 Feb; 12(1):1281. PubMed ID: 33627663
[TBL] [Abstract][Full Text] [Related]
25. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
An S; Fu L
EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
[TBL] [Abstract][Full Text] [Related]
26. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.
Leverson JD; Phillips DC; Mitten MJ; Boghaert ER; Diaz D; Tahir SK; Belmont LD; Nimmer P; Xiao Y; Ma XM; Lowes KN; Kovar P; Chen J; Jin S; Smith M; Xue J; Zhang H; Oleksijew A; Magoc TJ; Vaidya KS; Albert DH; Tarrant JM; La N; Wang L; Tao ZF; Wendt MD; Sampath D; Rosenberg SH; Tse C; Huang DC; Fairbrother WJ; Elmore SW; Souers AJ
Sci Transl Med; 2015 Mar; 7(279):279ra40. PubMed ID: 25787766
[TBL] [Abstract][Full Text] [Related]
27. The Present and Future of Novel Protein Degradation Technology.
Xia L; Liu W; Song Y; Zhu H; Duan Y
Curr Top Med Chem; 2019; 19(20):1784-1788. PubMed ID: 31644408
[TBL] [Abstract][Full Text] [Related]
28. Potent and Selective BCL-XL Inhibitors and PROTAC Compounds as Potential Cancer Treatment and Immunotherapy.
Kargbo RB
ACS Med Chem Lett; 2023 Jun; 14(6):702-704. PubMed ID: 37312850
[TBL] [Abstract][Full Text] [Related]
29. PROTAC-DB: an online database of PROTACs.
Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
[TBL] [Abstract][Full Text] [Related]
30. PROTACs: Novel tools for improving immunotherapy in cancer.
Li S; Chen T; Liu J; Zhang H; Li J; Wang Z; Shang G
Cancer Lett; 2023 Apr; 560():216128. PubMed ID: 36933781
[TBL] [Abstract][Full Text] [Related]
31. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras.
Wang Y; Han L; Liu F; Yang F; Jiang X; Sun H; Feng F; Xue J; Liu W
Colloids Surf B Biointerfaces; 2020 Apr; 188():110795. PubMed ID: 31991291
[TBL] [Abstract][Full Text] [Related]
32. PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.
Pettersson M; Crews CM
Drug Discov Today Technol; 2019 Apr; 31():15-27. PubMed ID: 31200855
[TBL] [Abstract][Full Text] [Related]
33. PROTACs- a game-changing technology.
Konstantinidou M; Li J; Zhang B; Wang Z; Shaabani S; Ter Brake F; Essa K; Dömling A
Expert Opin Drug Discov; 2019 Dec; 14(12):1255-1268. PubMed ID: 31538491
[No Abstract] [Full Text] [Related]
34. A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapy.
Chen X; Shen H; Shao Y; Ma Q; Niu Y; Shang Z
Transl Androl Urol; 2021 Feb; 10(2):954-962. PubMed ID: 33718095
[TBL] [Abstract][Full Text] [Related]
35. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
[TBL] [Abstract][Full Text] [Related]
36. Imbalanced expression of Bcl-xL and Bax in platelets treated with plasma from immune thrombocytopenia.
Qiao J; Liu Y; Li D; Wu Y; Li X; Yao Y; Niu M; Fu C; Li H; Ma P; Li Z; Xu K; Zeng L
Immunol Res; 2016 Apr; 64(2):604-9. PubMed ID: 26712345
[TBL] [Abstract][Full Text] [Related]
37. The application of ubiquitin ligases in the PROTAC drug design.
Chen Y; Jin J
Acta Biochim Biophys Sin (Shanghai); 2020 Jul; 52(7):776-790. PubMed ID: 32506133
[TBL] [Abstract][Full Text] [Related]
38. Proteolysis targeting chimeras (PROTACs) in cancer therapy.
Ocaña A; Pandiella A
J Exp Clin Cancer Res; 2020 Sep; 39(1):189. PubMed ID: 32933565
[TBL] [Abstract][Full Text] [Related]
39. Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL.
Nayak D; Lv D; Yuan Y; Zhang P; Hu W; Nayak A; Ruben EA; Lv Z; Sung P; Hromas R; Zheng G; Zhou D; Olsen SK
Nat Commun; 2024 Mar; 15(1):2743. PubMed ID: 38548768
[TBL] [Abstract][Full Text] [Related]
40. Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells.
Gayle SS; Sahni JM; Webb BM; Weber-Bonk KL; Shively MS; Spina R; Bar EE; Summers MK; Keri RA
J Biol Chem; 2019 Jan; 294(3):875-886. PubMed ID: 30482844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
